Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Ivermectin to Enter 1st Company-Sponsored COVID-19 Trial in Japan
July 2, 2021
- 3 Major Wholesalers, 7 Employees Found Guilty in Bid-Rigging Trial
July 2, 2021
- Ayumi to Leverage IT to Boost Sales and Marketing, Eyes More Licensing Deals
July 2, 2021
- Towa Now Curbs Shipments for 235 Products; 27 Added to Restriction List
July 2, 2021
- Kaken Grants European Rights for Efinaconazole to Almirall
July 2, 2021
- Mitsubishi Tanabe Rolls Out Oral Film ALS Drug in US
July 2, 2021
- Ex-BMS Exec Tsuji Takes Reins of Mundipharma Japan
July 2, 2021
- Solasia Files NDA for PTCL Drug in Japan
July 2, 2021
- Shionogi’s Chinese JV Commences RWD Collection, Analysis of Metabolic Diseases
July 2, 2021
- Takeda Revises Rules to Enable Fully Virtual Shareholders Meetings
July 1, 2021
- Nichi-Iko Expects Shipment Controls to Linger beyond April Next Year for 110 Products
July 1, 2021
- Eisai’s Sleep Inducer Dayvigo Now Available in Hong Kong
July 1, 2021
- AbbVie Japan Files Rinvoq for Ankylosing Spondylitis
July 1, 2021
- Taisho Grants Worldwide Rights for Antidepressant TS-121 to US Firm
July 1, 2021
- New BMS Japan Boots Up with Richer Cancer Assets as Celgene Merger Closes
July 1, 2021
- 2 Ono Employees Found Guilty for Onoact Bribery Charges; Scholarship Donation in Spotlight
June 30, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Japan Top Court Rejects Prosecutors’ Appeal in Diovan Case; Novartis Not Guilty
June 30, 2021
- Takeda CEO Takes Home 1.87 Billion Yen in FY2020
June 30, 2021
- Takeda’s Leuplin Supply Curb Remains More than 1 Year after Measure Set Off
June 29, 2021
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…